Ruxolitinib
- PDF / 169,385 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 27 Downloads / 166 Views
1 S
Small cell carcinoma: case report A 60-year-old woman developed small cell carcinoma during treatment with ruxolitinib for interferonopathy anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis (MDA 5 DM). The woman was referred to the hospital for MDA 5 DM with rapidly progressive interstitial pneumonia, muscular impairment and typical cutaneous features. She received treatment with high-dose cyclophosphamide, methylprednisolone and gammaglobulin; however, she remained corticosteroid dependent. Additionally, it was reported that she had been receiving treatment with ruxolitinib [dosage and route not stated] for interferonopathy MDA 5 DM. Blood detection of positive interferon signature showed clinical remission and the regression of the interferon signature. On follow-up 12 months later, a small cell carcinoma associated with ruxolitinib was discovered, which raised the question of a paraneoplastic syndrome [duration of treatment to reaction onset and outcome not stated]. Jalles C, et al. Severe MDA5 dermatomyositis associated with cancer and controlled by JAK inhibitor. Revue de Medecine Interne 41: 421-424, No. 6, Jun 2020. Available 803499511 from: URL: http://doi.org/10.1016/j.revmed.2020.02.015 [French; summarised from an English abstract]
0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Sep 2020 No. 1820
Data Loading...
